Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed pancreatic adenocarcinoma * Resectable disease (i.e., stage I or II disease) * No unresectable (i.e., locally advanced) disease * No tumor invasion into the stomach or duodenum * No CNS, brain, or systemic metastases PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * WBC \> 3,000/μL * ANC \> 1,500/μL * Platelet count \> 100,000/μL * Total bilirubin \< 2 mg/dL * AST or ALT \< 2.5 times upper limit of normal (ULN) * Creatinine \< 1.5 mg/dL * Creatinine clearance ≥ 50 mL/min * Urine protein:creatinine ratio \< 1.0 * Hemoglobin ≥ 9 g/dL (transfusion, epoetin alfa, or darbepoetin allowed) * INR \< 1.5 times ULN (except in patients receiving full-dose warfarin) * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No uncontrolled hypertension * No unstable angina * No New York Heart Association class II-IV congestive heart failure * No myocardial infarction or stroke within the past 6 months * No clinically significant peripheral vascular disease * No evidence of bleeding diathesis or coagulopathy * No significant traumatic injury within the past 28 days * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * No esophageal or gastric varices * No serious nonhealing wound, ulcer, or bone fracture PRIOR CONCURRENT THERAPY: * No prior therapy for pancreatic cancer * More than 4 weeks since prior …